Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein
Abstract Background Therapeutic antibodies for the treatment of neurological disease show great potential, but their applications are rather limited due to limited brain exposure. The most well-studied approach to enhance brain influx of protein therapeutics, is receptor-mediated transcytosis (RMT)...
Saved in:
Main Authors: | Marie-Lynn Cuypers, Tom Jaspers, Jarne Clerckx, Simon Leekens, Christopher Cawthorne, Guy Bormans, Frederik Cleeren, Nick Geukens, Bart De Strooper, Maarten Dewilde |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Fluids and Barriers of the CNS |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12987-025-00624-1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Optic Chiasmitis as an Isolated Manifestation of Myelin Oligodendrocyte Glycoprotein-Associated Disease – a Case Report
by: Nina Barankiewicz-Tyc, et al.
Published: (2024-10-01) -
Cryopreservation of primary neonatal rat oligodendrocytes and recapitulation of in vitro oligodendrocyte characteristics
by: Hanki Kim, et al.
Published: (2025-01-01) -
Clinical characteristics of anti-myelin oligodendrocyte glycoprotein antibody among aquaporin-4 negative neuromyelitis optica spectrum disorders in Egyptian patients
by: Sara I. Taha, et al.
Published: (2025-01-01) -
Single domain antibody-scFv conjugate targeting amyloid β and TfR penetrates the blood–brain barrier and interacts with amyloid β
by: Rebecca Faresjö, et al.
Published: (2024-12-01) -
Clusterin induced by OPC phagocytosis blocks IL-9 secretion to inhibit myelination in a model of Alzheimer's disease
by: Rebecca M. Beiter, et al.
Published: (2025-01-01)